Section
BEACON-HCC is a multidisciplinary, evidence-based North American consensus that updates HCC treatment allocation—integrating tumor biology, nuanced intrahepatic burden, vascular invasion, and newer modalities (EBRT, TARE, systemic–locoregio
Circulating extracellular vesicles carrying PD-1, PD-L1, and CTLA-4 can non-invasively predict responses and early resistance to immune checkpoint inhibitors in advanced hepatocellular carcinoma, improving patient stratification and managem
This study reveals significant sex-based disparities in access to robot-assisted surgery operative experience, showing female surgeons perform fewer robot-assisted procedures than males, potentially impacting career progression.
Adjuvant pegylated interferon following nucleos(t)ide analogue withdrawal in HBeAg-negative chronic hepatitis B significantly increases HBsAg loss rates and reduces severe hepatic flares over three years compared to withdrawal alone.
This study elucidates how faecal proteases and immune proteins distinctly activate enteric neurons in IBS subtypes, revealing subtype-specific pathological mechanisms and potential diagnostic biomarkers, highlighting novel therapeutic targe
This prospective study confirms that liver stiffness measurements by Fibroscan® strongly predict transplant-free survival in primary sclerosing cholangitis patients, validating both static values and dynamic changes as vital prognostic mark
This mediation analysis of a phase 2 MASH trial reveals that survodutide improves liver inflammation and fibrosis predominantly through weight-independent mechanisms, highlighting a potential direct hepatic effect beyond weight reduction.
Rapid skeletal muscle loss occurs in a significant subset of cirrhosis patients and independently predicts waitlist mortality, highlighting sarcopenia as a critical therapeutic target in liver disease management.
Postoperative colonic ischemia is a rare but severe complication after colectomy for colorectal cancer, primarily linked to specific resection types and vascular comorbidities, significantly impacting patient morbidity and mortality.
RIPPLY1 suppresses cancer stemness by targeting TBX19, improving prognosis in CTNNB1-mutated hepatocellular carcinoma through inhibition of tumor progression.
A large-scale proteomic study identified distinct MASLD subtypes influenced by sex differences and developed a four-protein score predicting all-cause mortality, advancing personalized risk assessment beyond traditional liver-centric models
A novel AI model, SÉMIL, integrating vision-language and multiple instance learning, improves prognostic accuracy for stage II colorectal cancer by refining risk stratification beyond current clinical assessments, especially within NCCN hig
The phase 3 TORCH trial demonstrates that adding selective radiofrequency ablation after transarterial chemoembolization significantly improves progression-free and overall survival in patients with unresectable liver-confined hepatocellula
New obesity definitions reclassify many MASLD patients as obese but do not improve prediction of liver-related events over BMI alone, according to a multinational cohort study.
A multicentre RCT found that smartphone-based self-guided hypnotherapy did not meet non-inferiority to in-person therapy for IBS abdominal pain, though both hypnotherapy arms outperformed psychoeducation.
The WONDER-01 trial found that immediate endoscopic necrosectomy after drainage for necrotizing pancreatitis reduced median time to clinical success by 15 days compared to a step-up approach, with similar adverse events.
This cohort study compares long-term survival and recurrence in esophageal adenocarcinoma patients achieving pathological complete response (pCR) after neoadjuvant FLOT chemotherapy versus CROSS chemoradiotherapy, highlighting better outcom
Highlight Portal vein thrombosis (PVT) in cirrhosis involves unique structural and cellular changes, including eccentric...
Introduction Inflammatory bowel diseases (IBD)—ulcerative colitis (UC) and Crohn’s disease (CD)—are characterized by chronic intestinal...
This study unravels how tumour-derived NGAL induces NETs that reprogram fibroblast subtypes via ITGA5, promoting immunosuppression and tumour progression in pancreatic ductal adenocarcinoma, suggesting combinatorial therapies to enhance imm
